Ultima-Tirzepatide

ACTIVE HALF-LIFE 5 days
CLASSIFICATION Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE GIP/GLP-1 RA

Introducing Tirzepatide, a revolutionary synthetic peptide renowned for its effectiveness in lowering blood sugar levels. This powerful compound stimulates insulin secretion during both the initial and sustained phases while simultaneously reducing glucagon levels in response to glucose fluctuations.

Tirzepatide is not just about managing blood sugar; it also slows gastric emptying, lowers fasting and post-meal glucose levels, curbs appetite, and supports weight loss for individuals with type 2 diabetes. Moreover, it enhances insulin sensitivity, making it a comprehensive solution for diabetes management.

Uniquely designed, Tirzepatide features a C20 fatty diacid linked via a hydrophilic connector at the lysine position 20. This innovative structure ensures a robust binding to albumin in the bloodstream, effectively extending its active half-life.

The GLP-1 (glucagon-like peptide-1) receptors, found in various organs including pancreatic beta-cells and the gastrointestinal tract, are crucial in regulating blood sugar levels and are closely tied to the development of type 2 diabetes. GLP-1R signaling significantly influences insulin secretion, delays gastric emptying, lowers glucagon production, and promotes weight loss through the activation of appetite-suppressing pathways in the brain. Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are vital peptide hormones that help maintain glucose balance, primarily by stimulating insulin release from pancreatic beta-cells, with GIP being the leading incretin hormone after meals.

While the exact mechanism of Tirzepatide remains a subject of study, its dual activation of GIP and GLP-1 receptors is believed to play a significant role in its blood sugar and weight management effects. Research suggests that the combination of GIP with a GLP-1R agonist produces a more substantial insulin response and better suppression of glucagon secretion than using either hormone alone. Tirzepatide demonstrates a high affinity for both GIP and GLP-1R, showing comparable binding to GIP receptors as native GIP, while its affinity for GLP-1R is five times lower than that of native GLP-1. This innovative drug effectively activates GLP-1R signaling to enhance glucose-dependent insulin secretion, leveraging both GIP receptors (GIPR) and GLP-1R. However, further research is needed to fully understand the impact of GIPR activation on blood sugar and weight control, as findings across preclinical and clinical studies have shown some inconsistencies.